Baudax Bio P/B

Mitä Baudax Bio tekee? Baudax Bio Inc, a pharmaceutical company based in Malvern, Pennsylvania, is engaged in the development and commercialization of products for hospital and acute care settings. The company, which went public via an IPO on November 14, 2019, currently employs nine full-time staff. Its lead product candidate is ANJESO injection, a cyclooxygenase-2 (COX-2) preferential non-steroidal anti-inflammatory drug designed for the management of moderate to severe pain. ANJESO may be used alone or in combination with other non-NSAID analgesics. Baudax Bio's pipeline includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, intended for use as muscle paralyzing agents during intubation and surgical procedures. The company is developing an intermediate-acting NMBA called BX-1000, an ultrashort-acting NMBA named BX-2000, and a reversal agent specific to its NMBAs. Additionally, Baudax Bio is exploring the discovery and development of Treg-based cell therapies for autoimmune diseases. The company's website is www.baudaxbio.com. Baudax Bio on yksi Eurpooliin suosituimmista yhtiöistä.